The Morning Call (Sunday)

How concerned do you need to be about new COVID-19 variants?

- By Lisa Jarvis

Some rather alarming headlines recently circulated about the newest members of the omicron family. “Nightmare COVID variant,” read one. “The most immune-evasive COVID variants yet.”

Or, as one would-be pandemic influencer said in a tweet shared thousands of times: “MOTHER OF GOD… #COVID variants worse than CDC has been admitting.”

Apparently, it’s spooky season for COVID-19 variants.

Or not. These fear-mongering headlines and viral all-caps tweets confuse and mislead the public about the dangers of the new omicron descendant­s. Worse, they potentiall­y undermine a critical message: COVID-19 vaccines still provide good protection against all of these variants.

Much of the recent hubbub arose because the Centers for Disease Control updated its estimates of circulatin­g variants, noting that BQ.1 and BQ.1.1., both descendant­s of the by-now familiar BA.5, combined now account for about 11% of infections in the U.S. That’s up from less than 1% a month ago. Meanwhile, the XBB variant has been making inroads in Asia.

The reason for the panicked headlines is that these new omicron family members are capable of “immune escape” — a phrase that makes it sound as if the virus has evolved past our currently available tools.

In reality, the virus has mutated in a way that allows it to get around some of the frontlines of our immune defense system, our neutralizi­ng antibodies. The world has paid a lot of attention to neutralizi­ng antibodies over the past two years because they are easy to measure, and thus became a proxy for vaccine effectiven­ess.

But our immune response is more nuanced than neutralizi­ng antibodies, particular­ly given how much of the population has been both vaccinated and infected with some earlier form of omicron, says Jeremy Kamil, virologist and professor of microbiolo­gy and immunology at Louisiana State University Health Shreveport. Vaccinated and previously infected people have other robust lines of defense, such as memory T cells and B cells. People previously infected also have additional immune cells in the respirator­y tract.

“I’m not a fan of that word ‘escape.’ I think a better word is ‘erosion,’ ” says Katelyn Jetelina, author of the popular newsletter Your Local Epidemiolo­gist.

In the end, all of this means that the new variants popping up might mean we see more virus transmissi­on — and more infections. But the shots still do a good job keeping people safe from severe infections, hospitaliz­ations and death.

That message could get lost in the mix, and that’s dangerous when enthusiasm for COVID-19 shots is so low — as of last week, only 14.8 million people in the U.S. had received the updated bivalent shot. That’s less than 7% of the more than 226 million Americans eligible for the booster.

The other piece of the story that is too often overlooked is that these new omicron variants can still be combated with Pfizer’s antiviral Paxlovid. The drug targets a part of the virus that has remained fairly steady even as the virus has changed, and is shown to be effective at preventing serious cases of the disease — particular­ly in unvaccinat­ed and older population­s.

However, there is one reason to be concerned about BQ1, BQ1.1 and XBB. These new variants threaten to disarm the last two effective monoclonal antibody therapies, AstraZenec­a’s Evusheld (used to prevent infection) and Lilly’s bebtelovim­ab (used to treat infections). The drugs have been important tools to protect immunocomp­romised people and others at high risk of serious disease. Companies are working on updated antibodies and the Food and Drug Administra­tion must continue to speed them through emergency use authorizat­ions.

So when do we worry? Those alarmist headlines might be justified if an entirely new branch in the SARS-CoV-2 family tree emerges. That’s not nearly as likely as a scenario where more omicron-like variants continue to emerge, but given the twists and turns this virus has taken, “We have to remain humble,” Jetelina says.

And Kamil says if you’re someone who hasn’t had either COVID-19 or a booster shot in the past six months, now would be a good time to go get one. Based on what other countries are seeing, a winter wave driven by one or several of these variants is likely to materializ­e. But that will only result in another wave of deaths if we stop trusting our still-good defenses.

Newspapers in English

Newspapers from United States